Radioligand therapy extends progression-free survival with manageable safety profile in advanced prostate cancer
New data on prolonged prostate-specific antigen (PSA) progression and adverse events grouped by safety topic of interest from the PSMAfore study underscore the statistically significant and clinically meaningful radiographic ...
Jun 10, 2024
0
0